D. Juzar, A. Muzakkir, Y. Ilhami, N. Taufiq, T. Astiawati, I. M. J. R A, M. Pramudyo, Andria Priyana, Afdhalun Hakim, S. Anjarwani, Jusup Endang, B. Widyantoro
{"title":"Management of Acute Coronary Syndrome Indonesia : Insight from One ACS Multicenter Registry","authors":"D. Juzar, A. Muzakkir, Y. Ilhami, N. Taufiq, T. Astiawati, I. M. J. R A, M. Pramudyo, Andria Priyana, Afdhalun Hakim, S. Anjarwani, Jusup Endang, B. Widyantoro","doi":"10.30701/ijc.1406","DOIUrl":null,"url":null,"abstract":"Background \nAcute coronary syndrome (ACS) is a life-threatening disorder which contributes to high morbidity and mortality in the world. Registry of ACS offers a great guidance for improvement and research. We collated a multicentre registry to gain information about demographic, management, and outcomes of ACS in Indonesia. \nMethods \nIndONEsia Acute Coronary Syndrome Registry (One ACS Registry) was a prospective nationwide multicenter registry with 14 hospitals participating in submitting data of ACS via standardized electronic case report form (eCRF). Between July 2018 and June 2019, 7634 patients with ACS were registered. This registry recorded baseline characteristics; onset, awareness, and transfer time; physical examination and additional test; diagnosis; in-hospital medications and intervention; complications; and in-hospital outcomes. \nResults \nNearly half of patients (48.8%) were diagnosed with STE-ACS. Most prevalent risk factors were male gender, smoking, hypertension. Patients with NSTE-ACS tended to have more concomitant diseases including diabetes mellitus, dyslipidemia, prior AMI, HF, PCI, and CABG. Majority of ACS patients in our registry (89.4%) were funded by national health coverage. Antiplatelet, anticoagulant, antihypertensive, and statins were prescribed as 24-hours therapy and discharge therapy; however presription of potent P2Y12 inhibitor was low. More STE-ACS patients underwent reperfusion therapy than non-reperfusion (65.2% vs. 34.8%), and primary PCI was the most common method (45.7%). Only 21.8% STE-ACS patients underwent reperfusion strategy within 0-3 hours of onset. Invasive strategy performed in 17.6% of NSTE-ACS patients, and only 6.7% performed early (within <24 hours). Patients underwent early invasive strategy had a shorter median LoS than late invasive strategy (P<0.001). A shorter median LoS also found in intermediate and low risk patients. Mortality rate in our ACS patients was 8.9%; STE-ACS patients showed higher mortality than NSTE-ACS (11.7 vs. 6.2%). \nConclusion \nOur registry showed a comparable proportion between STE- and NSTE-ACS patients, with male gender predominant in middle age. Both STE- and NSTE-ACS sharing the same risk factors. We need an improvement in referral time, especially in patients with STE-ACS. Evidence from our registry showed that there are two issues that need to be addressed in order to improve ACS outcomes: optimal and adequate medical treatment and invasive strategy.","PeriodicalId":32916,"journal":{"name":"Majalah Kardiologi Indonesia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Majalah Kardiologi Indonesia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30701/ijc.1406","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Acute coronary syndrome (ACS) is a life-threatening disorder which contributes to high morbidity and mortality in the world. Registry of ACS offers a great guidance for improvement and research. We collated a multicentre registry to gain information about demographic, management, and outcomes of ACS in Indonesia.
Methods
IndONEsia Acute Coronary Syndrome Registry (One ACS Registry) was a prospective nationwide multicenter registry with 14 hospitals participating in submitting data of ACS via standardized electronic case report form (eCRF). Between July 2018 and June 2019, 7634 patients with ACS were registered. This registry recorded baseline characteristics; onset, awareness, and transfer time; physical examination and additional test; diagnosis; in-hospital medications and intervention; complications; and in-hospital outcomes.
Results
Nearly half of patients (48.8%) were diagnosed with STE-ACS. Most prevalent risk factors were male gender, smoking, hypertension. Patients with NSTE-ACS tended to have more concomitant diseases including diabetes mellitus, dyslipidemia, prior AMI, HF, PCI, and CABG. Majority of ACS patients in our registry (89.4%) were funded by national health coverage. Antiplatelet, anticoagulant, antihypertensive, and statins were prescribed as 24-hours therapy and discharge therapy; however presription of potent P2Y12 inhibitor was low. More STE-ACS patients underwent reperfusion therapy than non-reperfusion (65.2% vs. 34.8%), and primary PCI was the most common method (45.7%). Only 21.8% STE-ACS patients underwent reperfusion strategy within 0-3 hours of onset. Invasive strategy performed in 17.6% of NSTE-ACS patients, and only 6.7% performed early (within <24 hours). Patients underwent early invasive strategy had a shorter median LoS than late invasive strategy (P<0.001). A shorter median LoS also found in intermediate and low risk patients. Mortality rate in our ACS patients was 8.9%; STE-ACS patients showed higher mortality than NSTE-ACS (11.7 vs. 6.2%).
Conclusion
Our registry showed a comparable proportion between STE- and NSTE-ACS patients, with male gender predominant in middle age. Both STE- and NSTE-ACS sharing the same risk factors. We need an improvement in referral time, especially in patients with STE-ACS. Evidence from our registry showed that there are two issues that need to be addressed in order to improve ACS outcomes: optimal and adequate medical treatment and invasive strategy.
背景急性冠脉综合征(ACS)是一种危及生命的疾病,在世界范围内具有很高的发病率和死亡率。ACS的注册为改进和研究提供了很好的指导。我们整理了一个多中心注册表,以获得有关印度尼西亚ACS的人口统计、管理和结果的信息。方法印度尼西亚急性冠脉综合征登记处(One ACS Registry)是一个前瞻性的全国性多中心登记处,有14家医院通过标准化电子病例报告表(eCRF)提交ACS数据。2018年7月至2019年6月期间,登记了7634例ACS患者。该注册表记录了基线特征;发病、意识和转移时间;体格检查和附加检查;诊断;院内用药和干预;并发症;还有住院的结果。结果近一半(48.8%)的患者诊断为STE-ACS。最常见的危险因素是男性、吸烟、高血压。NSTE-ACS患者往往有更多的合并疾病,包括糖尿病、血脂异常、既往AMI、HF、PCI和CABG。在我们的登记中,大多数ACS患者(89.4%)是由国家健康保险资助的。抗血小板、抗凝、降压、他汀类药物作为24小时治疗和出院治疗;而强效P2Y12抑制剂的处方量较少。接受再灌注治疗的STE-ACS患者多于不接受再灌注治疗的患者(65.2% vs. 34.8%),其中首次PCI是最常见的方法(45.7%)。只有21.8%的STE-ACS患者在发病0-3小时内采用再灌注策略。17.6%的NSTE-ACS患者采用了有创策略,只有6.7%的患者在早期(<24小时)采用了有创策略。早期有创患者的中位LoS短于晚期有创患者(P<0.001)。中、低危患者的中位LoS也较短。ACS患者的死亡率为8.9%;STE-ACS患者的死亡率高于NSTE-ACS (11.7% vs. 6.2%)。结论:我们的注册表显示STE- acs和NSTE-ACS患者的比例相当,以中年男性为主。STE-和NSTE-ACS具有相同的危险因素。我们需要改善转诊时间,特别是STE-ACS患者。我们登记处的证据表明,为了改善ACS的结果,有两个问题需要解决:最佳和充分的药物治疗和侵入性策略。